Christina Herder
Idogen about the conference in Boston and the plans ahead
Christina Herder, acting CEO of the biotechnology company Idogen, joined BioStock's studio to talk about the company's participation at the 6th...
Idogen strengthens fund for clinical study in 2023
The subscription period has now begun for Idogen's rights issue, which...
Idogen strengthens the board with Jan Holgersson
Idogen strengthens the board with Professor Jan Holgersson as...
Idogen's acting CEO comments on the share issue
Biotechnology company Idogen is in the clinical phase with...
BioStock Investor Meeting: Interview with Idogen
In connection with the BioStock Investor Meeting in Stockholm...
BioStock Investor Meeting: Idogen presents
Idogen's newly appointed acting CEO Christina Herder took the opportunity...
Idogen's acting CEO talks about plans for the fall
hristina Herder has been appointed as the new acting CEO...
BioStock Investor Meeting September 14
On September 14th it was time again for...
Notes
iZafe takes the next step in the Nordics – begins Finnish partnership for Dosell
Senzime's partner receives FDA approval for TetraGraph module
Ellen sells the business for SEK 13,3 million
Oncopeptides increases sales in the second quarter
Alvotech acquires Ivers-Lee Group in Switzerland
NEWSLETTER
NEWS
Merck gears up in lung diseases with giant acquisition
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
AlzeCure Pharma: “We have good momentum”
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
